PNC Financial Services Group Inc. Buys Shares of 28,903 ProQR Therapeutics (NASDAQ:PRQR)

PNC Financial Services Group Inc. purchased a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 28,903 shares of the biopharmaceutical company’s stock, valued at approximately $77,000.

Several other hedge funds also recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in shares of ProQR Therapeutics during the 4th quarter worth about $260,000. M&T Bank Corp acquired a new stake in ProQR Therapeutics during the fourth quarter worth about $330,000. Ballentine Partners LLC acquired a new stake in ProQR Therapeutics during the fourth quarter worth about $61,000. Finally, BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. 32.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PRQR has been the topic of several recent research reports. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, March 14th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective for the company. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Monday, March 10th. Finally, HC Wainwright raised their price target on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, ProQR Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.50.

ProQR Therapeutics Stock Down 2.4 %

Shares of ProQR Therapeutics stock opened at $1.61 on Wednesday. ProQR Therapeutics has a 12-month low of $1.59 and a 12-month high of $4.62. The stock has a market capitalization of $169.39 million, a P/E ratio of -5.03 and a beta of 0.24. The company has a 50-day simple moving average of $2.13 and a 200 day simple moving average of $2.61.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).